Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22875430 | 0.96 | ACHE (0.59) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL24315879 | 0.94 | ACHE (0.62) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL8362658 | 0.94 | ACHE (0.62) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL680627 | 0.91 | ACHE (0.47) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL27425161 | 0.89 | ACHE (0.45) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL20756942 | 0.88 | ACHE (0.46) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL21946386 | 0.84 | NCF1 (0.42) | ACHECHRM5ADRA2CTLR9TLR8 | |
| SCHEMBL26157383 | 0.84 | ACHE (0.55) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL23484704 | 0.84 | ACHE (0.55) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL24315878 | 0.83 | ACHE (0.50) | ACHECHRM5ADRA2COPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024036254-A2 | SYNTHETIC PROCESSES AND INTERMEDIATES FOR PREPARING THERAPEUTIC AZAKETOLIDES | ZIKANI THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | ACHE 1743/4885CHRM5 2722/4885ADRA2C 2238/4885 |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | ACHE 1743/4885CHRM5 2722/4885ADRA2C 2238/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | ACHE 1893/4885CHRM5 4386/4885ADRA2C 3950/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | ACHE 3575/4885CHRM5 4860/4885ADRA2C 3592/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | ACHE 2387/4885CHRM5 4805/4885ADRA2C 3645/4885 |
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, WNT1 | ACHE 1743/4885CHRM5 2722/4885ADRA2C 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.